Clinical Trials Logo

Filter by:
NCT ID: NCT04787523 Completed - Rectal Neoplasms Clinical Trials

Rectrospect - a Retrospective Study of Treatment Response

Rectrospect
Start date: October 1, 2020
Phase:
Study type: Observational

Biopisies from patients diagnosed with rectal cancer between 2007-2019 will be cut into 4-6 micrometer thin sections for morphology and immunostaining. Every section will be numbered with a code that is connected to the patients personal identification number and the code list will be kept separately from the biopsies in a password protected file on the Sahlgrenska University Hospital server. Patient data and outcome regarding response to treatment will be collected from patient charts and the Swedish ColoRectal Cancer Registry, but all data will be numbered with the same code number and all results will be kept away from the code list. In order to achieve the stated aims, that is, to study how the molecular and cellular characteristics of the tumour and its surrounding microenvironment as well as the interaction of tumour cells and immune cells affect treatment response, several molecular and cellular techniques and assays may be applied.

NCT ID: NCT04784936 Completed - Stroke Clinical Trials

Identification of Stroke at the Emergency Medical Dispatch Center

IdStroke
Start date: September 2010
Phase:
Study type: Observational

A study to investigate how stroke is identified and whether FAST, face-arm-speech test, is used in the emergency medical dispatch centre in Stockholm. The study will also investigate when FAST is used, does it increase the identification of stroke? And if other factors can be identified as "markers" for more effective identification of stroke during the emergency call.

NCT ID: NCT04783935 Completed - Multiple Sclerosis Clinical Trials

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Start date: March 10, 2021
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568_0022 (NCT03364036).

NCT ID: NCT04781296 Completed - CT Photon-Counting Clinical Trials

Spectral CT With Advanced CT Technology

Start date: April 19, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to collect data to evaluate feasibility of the using photon-counting CT in a clinical setting.

NCT ID: NCT04780815 Completed - Healthy Volunteers Clinical Trials

An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers

Start date: March 16, 2020
Phase: N/A
Study type: Interventional

This is a single-center, exploratory positron emission tomography (PET) study of deposition, disposition and brain uptake [11C]nicotine when given to smokers as two different formulations via mybluTM e-cigarette system.

NCT ID: NCT04778215 Completed - Low Back Pain Clinical Trials

Prevention and Treatment of Low Back Pain in Young Female TeamGym Gymnasts

Start date: March 2009
Phase: N/A
Study type: Interventional

Specific stabilization training targeting the deep trunk muscles has shown good effect in the rehabilitation of Low Back Pain (LBP) in young female TeamGym (TG) gymnasts. However, if this training can prevent LBP in this young population remains to be investigated. The aim of the present study was to investigate if a specific lumbar stabilization program can reduce and prevent LBP in young female TG gymnasts.

NCT ID: NCT04776577 Completed - Coronary Disease Clinical Trials

Assessment of Coronary Pressure Using the Combined Guidewire and Catheter Wirecath

Start date: February 25, 2021
Phase: N/A
Study type: Interventional

In summary, the purpose of the study is to evaluate whether the Wirecath device can be used as a standard pressure wire in a safe and efficient way.

NCT ID: NCT04771234 Completed - Chronic Insomnia Clinical Trials

Digital Psychological Self-care for Sleep Problems

Start date: February 25, 2021
Phase: N/A
Study type: Interventional

In this non-randomized treatment feasibility pilot we want to explore if a simplified version of CBT-i as a non-therapist-guided digital tool can work; if the digital tool is perceived as user friendly and if participants' insomnia severity is improved following four weeks of treatment.

NCT ID: NCT04767711 Completed - Bone Loss Clinical Trials

Prevention of Glucocorticoid Induced Impairment of Bone Metabolism

Start date: May 16, 2022
Phase: N/A
Study type: Interventional

Glucocorticoid (GC) therapy is used to treat a variety of inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, bronchial asthma, allergies, ankylosing spondylitis and some forms of cancers. Despite the well-known side-effects, GC treatment is widely used. Oral GC therapy leads to a rapid and profound effects on bone metabolism, with increased osteoblast apoptosis and prolonged osteoclast survival, which increases bone resorption, resulting in bone loss, and a subsequent increased fracture risk. Within days of high dose oral GC, glucose tolerance decreases and bone turnover is shifted in favour of less bone formation and increased bone resorption. Bone formation and bone resorption can be estimated by measuring serum bone turnover markers. The gut microbiota is involved in regulating bone metabolism and recently it was demonstrated that Lactobacillus reuteri 6475 (LR) could reduce bone loss over 12 months by half in older women. In a recent experimental study, it was discovered that mice treated either with broad spectrum antibiotics, eradicating gut microbiota, or with LR did not experience GC induced bone loss in the spine and femur. L. reuteri has been widely studied in clinical trials and has been shown to have probiotic, health-promoting effects in both adults and children. The aim of this planned randomized, double-blind, placebo-controlled trial is to investigate if daily supplementation with LR, compared to placebo, can prevent the negative effects of oral glucocorticoid (GC) on bone turnover and on blood glucose regulation in healthy young adult men and women. If LR is able to prevent deleterious side effects, such as bone loss and impaired glucose tolerance, of oral GC treatment, the probiotic could potentially be recommended and used to improve health in a substantial yearly number of patients treated with GC.

NCT ID: NCT04767321 Completed - Clinical trials for Nasal Decolonization of Staphylococcus Aureus

A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

Start date: February 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa, double-blind, placebo-controlled, randomised study designed to evaluate the safety, tolerability, exploratory efficacy and exposure of LTX-109 administered topically to the anterior nares in subjects with persistent carriage of S. aureus (methicillin-susceptible S. aureus [MSSA] and/or methicillin-resistant S. aureus [MRSA]).